Jennifer Faig1, Michael Haughton2, Richard C Taylor3, Ralph B D'Agostino4, Megan J Whelen5, Kori A Porosnicu Rodriguez6, Marcelo Bonomi2, Mariana Murea7, Mercedes Porosnicu2. 1. Beth Israel Deaconess Medical Center, Boston, MA. 2. Departments of Internal Medicine, Section on Hematology and Oncology. 3. Internal Medicine. 4. Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest University Health Sciences, Medical Center Boulevard. 5. Comprehensive Cancer Center of Wake Forest University, Medical Center Boulevard, Winston-Salem, NC. 6. Wake Forest School of Medicine, Medical Center Boulevard. 7. Nephrology, Wake Forest School of Medicine, Medical Center Boulevard.
Abstract
OBJECTIVES: Cisplatin remains the pivotal chemotherapy in squamous cell carcinoma of the head and neck (SCCHN), with nephrotoxicity considered the dose-limiting toxicity. The purpose of our study was to propose an outpatient high-dose cisplatin protocol aimed at preventing nephrotoxicity and to analyze the results of its utilization in patients with SCCHN treated with concurrent radiotherapy. MATERIALS AND METHODS: We retrospectively evaluated 82 SCCHN patients treated with outpatient high-dose cisplatin concurrent with radiotherapy at our institution. Acute kidney injury (AKI) and chronic kidney disease were defined by Kidney Disease Improving Global Outcomes criteria. Associated factors were identified using analysis of covariance models for categorical variables and adjusted Pearson correlations for continuous variables. RESULTS: The incidence of AKI during treatment was 34.2%. With a median follow-up of 25.7 months, the average decrease in estimated glomerular filtration rate was 12.57 mL/min/1.73 m (SD=18.58). At 1 year and at last follow-up, 5.4% and 4.4% of patients had estimated glomerular filtration rate <60 mL/min/1.73 m. Predictors associated with AKI and chronic kidney disease were: lower baseline weight and creatinine, higher baseline creatinine clearance, smoking, female sex, African American race, hypertension, and increased hydration and magnesium replacement requirements. CONCLUSIONS: We encountered limited early and late nephrotoxicity. Importantly, nephrotoxicity was not the main dose-limiting toxicity. Our results emphasize the importance of close monitoring and additional replacement of water and electrolytes as needed. A consistent method of measuring and reporting chemotherapy-induced nephrotoxicity would be a valuable contribution to the literature.
OBJECTIVES:Cisplatin remains the pivotal chemotherapy in squamous cell carcinoma of the head and neck (SCCHN), with nephrotoxicity considered the dose-limiting toxicity. The purpose of our study was to propose an outpatient high-dose cisplatin protocol aimed at preventing nephrotoxicity and to analyze the results of its utilization in patients with SCCHN treated with concurrent radiotherapy. MATERIALS AND METHODS: We retrospectively evaluated 82 SCCHN patients treated with outpatient high-dose cisplatin concurrent with radiotherapy at our institution. Acute kidney injury (AKI) and chronic kidney disease were defined by Kidney Disease Improving Global Outcomes criteria. Associated factors were identified using analysis of covariance models for categorical variables and adjusted Pearson correlations for continuous variables. RESULTS: The incidence of AKI during treatment was 34.2%. With a median follow-up of 25.7 months, the average decrease in estimated glomerular filtration rate was 12.57 mL/min/1.73 m (SD=18.58). At 1 year and at last follow-up, 5.4% and 4.4% of patients had estimated glomerular filtration rate <60 mL/min/1.73 m. Predictors associated with AKI and chronic kidney disease were: lower baseline weight and creatinine, higher baseline creatinine clearance, smoking, female sex, African American race, hypertension, and increased hydration and magnesium replacement requirements. CONCLUSIONS: We encountered limited early and late nephrotoxicity. Importantly, nephrotoxicity was not the main dose-limiting toxicity. Our results emphasize the importance of close monitoring and additional replacement of water and electrolytes as needed. A consistent method of measuring and reporting chemotherapy-induced nephrotoxicity would be a valuable contribution to the literature.
Authors: Neife Aparecida Guinaim dos Santos; Maria Augusta Carvalho Rodrigues; Nadia Maria Martins; Antonio Cardozo dos Santos Journal: Arch Toxicol Date: 2012-03-01 Impact factor: 5.153
Authors: Jay S Cooper; Qiang Zhang; Thomas F Pajak; Arlene A Forastiere; John Jacobs; Scott B Saxman; Julie A Kish; Harold E Kim; Anthony J Cmelak; Marvin Rotman; Robert Lustig; John F Ensley; Wade Thorstad; Christopher J Schultz; Sue S Yom; K Kian Ang Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-30 Impact factor: 7.038
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Júlia C F Quintanilha; Marília B Visacri; Vanessa M Sousa; Larissa B Bastos; Camila O Vaz; João P O Guarnieri; Laís S Amaral; Carina Malaguti; Carmen S P Lima; Anibal E Vercesi; Patricia Moriel Journal: Mol Cell Biochem Date: 2017-08-21 Impact factor: 3.396
Authors: Shveta S Motwani; Gearoid M McMahon; Benjamin D Humphreys; Ann H Partridge; Sushrut S Waikar; Gary C Curhan Journal: J Clin Oncol Date: 2018-01-10 Impact factor: 44.544
Authors: Maurice J D L van der Vorst; Elisabeth C W Neefjes; Elisa C Toffoli; Jolanda E W Oosterling-Jansen; Marije R Vergeer; C René Leemans; Menno P Kooistra; Jens Voortman; Henk M W Verheul Journal: BMC Cancer Date: 2019-11-08 Impact factor: 4.430